CellPro, Nexell, VimRx deal

Nexell completed its acquisition of CPRO's assets for $3 million in VMRX securities (1.9 million shares) (see BioCentury, Dec. 21, 1998). Nexell launched a diagnostics division to house the diagnostics assets acquired from CPRO and focus on technologies to detect and measure low numbers of residual tumor cells to improve cancer treatments. ...